Stryker Corporation

New York Stock Exchange
Back to all articles
Slightly Bullish +20

SYK Q1 Deep Dive: Cyber Incident Disrupts Operations, Management Reiterates Full-Year Outlook

📉 Stryker reported Q1 revenue of $6.02 billion, missing Wall Street estimates of $6.34 billion due to a 5% shortfall.

💸 Non-GAAP earnings per share were $2.60, significantly below the analyst consensus of $2.98 by 12.9%.

⚠️ A late-quarter cyber incident caused operational shutdowns and production delays that disrupted revenue recognition across the company.

🤖 Management reaffirmed its full-year adjusted EPS guidance of $15 at the midpoint despite Q1 underperformance.

📈 Operating margins expanded to 15.5%, up from 14.3% in the previous year, offsetting some impact from the cyber event.

🔧 Manufacturing operations were fully restored by early April, with leadership crediting effective backup systems for rapid recovery.

🤖 Stryker achieved its best-ever first quarter for Mako robotic system installations, driven by high utilization and surgeon feedback.

🔄 The company reorganized into a new Ortho Tech division to streamline innovation and combine key product portfolios.

🤝 Stryker is nearing the acquisition of Amplitude Vascular Systems to expand its peripheral vascular market presence.

💰 Deferred revenue from Q1 delays is expected to be recognized throughout the remainder of the year in varying cadences.

🚀 New products like Mako Shoulder and Pangea trauma platform approvals are anticipated to drive continued growth.

🛡️ Management plans investments in cybersecurity and operational resilience following lessons learned from the recent incident.

💹 Input cost inflation from tariffs and raw materials will be managed through procurement initiatives and operational discipline.

📉 The stock price dropped from $315.28 to $293.91 following the earnings announcement and Q1 miss.

Bullish Signals
  • Management reiterated its full-year Adjusted EPS guidance of $15 at the midpoint, signaling confidence that Q1 impacts will be recovered over the rest of the year.
  • Operating margin expanded to 15.5% from 14.3% in the same quarter last year, demonstrating underlying operational strength.
  • Stryker reported its best-ever first quarter for Mako robotic system installations, driven by high utilization and positive feedback from surgeons.
  • The upcoming launch of the Mako Shoulder on the latest platform is expected to further boost growth in the joint replacement franchise.
  • A new Ortho Tech division was established to combine key portfolios, which aligns product lines for better speed to market and operational efficiency.
  • Management highlighted a pending acquisition of Amplitude Vascular Systems (AVS) to expand presence in the peripheral vascular market, alongside ongoing evaluation of additional M&A opportunities.
  • The company expects full rollout of the Mako Shoulder and approvals for the Pangea trauma platform in Europe and Japan to drive above-market growth.
  • Stryker plans to offset input cost inflation and tariffs through procurement initiatives and operational discipline to achieve targeted operating margin improvement for the full year.
Risk Factors
  • Stryker missed Wall Street revenue expectations by 2.6% year-on-year ($6.02B vs $6.34B estimates) and underperformed on non-GAAP profit with actual EPS of $2.60 versus the $2.98 analyst consensus (a 12.9% miss).
  • Adjusted EBITDA missed estimates by 11.5% at $1.39 billion compared to $1.57 billion, with margins falling short of projected performance.
  • A late-quarter cyber incident disrupted global systems, causing production stoppages, delayed shipments, and uneven revenue recognition impacts across capital equipment and made-to-order product lines.
  • The company faces operational shutdowns and variability in business units due to the cyberattack, requiring ongoing investments in cybersecurity and operational resilience despite having restored manufacturing by early April.
  • Stock price fell from $315.28 to $293.91 immediately following the earnings report, reflecting market concerns over the quarter's execution and future recovery trajectory.
  • Analysts are closely monitoring the pace and completeness of revenue recovery from the cyber incident, specifically watching for delays in capital-intensive MedSurg products scheduled for Q3 and Q4 catch-up.
  • The company plans to offset input cost inflation from tariffs and rising raw material prices through procurement initiatives, creating potential margin pressure despite targeted improvements.
Full Analysis
Medical technology company Stryker reported first-quarter 2026 results that missed Wall Street expectations on both revenue and earnings due to the disruptive timing of a cybersecurity incident. The company's revenue rose 2.6% year-over-year to $6.02 billion, but this was significantly below analyst estimates of $6.34 billion, marking a 5% miss. Similarly, non-GAAP adjusted earnings per share came in at $2.60 per share, which was 12.9% lower than the consensus estimate of $2.98, while non-GAAP adjusted EBITDA fell to $1.39 billion against an expected $1.57 billion. Management attributed these misses primarily to a late-quarter cyber incident that caused global system disruptions, resulting in production stoppages, delayed shipments, and varied impacts on revenue recognition across different business units, with capital equipment and made-to-order products suffering more than consumables. Despite the quarter's underperformance, CEO Kevin Lobo stated that underlying demand remains healthy and the operational shutdowns constrained reported results rather than indicating a lack of customer interest or product viability. CFO Preston Wells noted that manufacturing operations were fully restored by early April thanks to swift action and effective backup systems that minimized permanent damage to customer relationships. Looking ahead for the remainder of 2026, Stryker has reiterated its full-year adjusted EPS guidance at $15 per share at the midpoint, unchanged from its previous outlook, expecting most lost sales from the cyber incident to be recovered over the rest of the year. Management outlined a specific recovery cadence where catch-up revenue is anticipated to begin in the second quarter for some businesses while extending into the second half for others, with orthopaedics expected to recover earlier than capital-intensive med-surg products. The company highlighted continued momentum in its robotic systems, reporting record first-quarter installations for its Mako robotic system and preparing for the launch of Mako Shoulder on the latest platform. Additionally, Stryker has reorganized its Ortho Tech division by combining portfolios to streamline innovation and is pursuing the acquisition of Amplitude Vascular Systems to expand into peripheral vascular markets. The company plans to maintain its full-year operating margin improvement targets despite first-half headwinds from input cost inflation, tariffs, and rising raw material prices through operational discipline and procurement initiatives. Investors will be watching the pace of revenue recovery from the cyber incident, specifically how quickly deferred sales are recognized across various product lines, as well as the execution on upcoming new product launches like Mako Shoulder and the Pangea trauma platform approvals in Europe and Japan. Stryker's stock traded at $293.91 following the earnings report, down from $315.28 prior to the announcement, reflecting immediate market reaction to the miss against expectations.